Podium to Practice: GI Cancers Symposium 2026 – KRAS G12D INHIBITOR IN MET PANCREAS CA

Podium to Practice: GI Cancers Symposium 2026 – KRAS G12D INHIBITOR IN MET PANCREAS CA

Podium to Practice: GI Cancers Symposium 2026
Explore more from your favourite experts – click their name to access their entire library of content.
Icon Chair Speaker

Chair

Dr. Scott Berry

Icon Chair Speaker

Panelists

Dr. Sharlene Gill

Dr. Marc Peeters

Studies / Trials Discussed

654 – Preliminary phase 1 results of INCB161734, a novel oral Kirsten rat sarcoma (KRAS) G12D inhibitor, as monotherapy or in combination with chemotherapy for advanced/metastatic pancreatic duct adenocarcinoma (PDAC).

Studies/trials discussed:

654 – Preliminary phase 1 results of INCB161734, a novel oral Kirsten rat sarcoma (KRAS) G12D inhibitor, as monotherapy or in combination with chemotherapy for advanced/metastatic pancreatic duct adenocarcinoma (PDAC).
Tagged